Non-Hodgkin Lymphoma trial readouts
registry pull 2026-08-19Primary-completion dates that listed drug and biotech companies filed with ClinicalTrials.gov for studies in Non-Hodgkin Lymphoma. They are the sponsor's own estimated windows, revised as a study runs — not announcement dates. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Upcoming readout windows
next 180 days · by month3 studies across 3 companies, in the next 180 days.
September 2026 1
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| CCCC | C4 Therapeutics, Inc. | Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple MyelomaNCT04756726Phase 1: Safety and tolerability of cemsidomide | Phase 1 | Active, not recruiting | 2026-09-30 | in 41 d | 2026-03-25 |
October 2026 1
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| BMY | Bristol-Myers Squibb | A Rollover Study of CC-122NCT05688475Number of participants with serious adverse events (SAEs) for participants who received at least 1 dose of CC-122 | Phase 1 | Active, not recruiting | 2026-10-31 | in 72 d | 2026-05-11 |
November 2026 1
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| ONC | BeOne Medicines | A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell MalignanciesNCT05006716Phase 1: Number of Participants with Adverse Events (AEs) | Phase 1/2 | Recruiting | Nov 2026 | ≤ 102 d | 2026-08-19 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Every registered study in Non-Hodgkin Lymphoma
most recently updated first174 studies match. Showing the first 100 of 174 studies — page through, or narrow the filters.
| Ticker | Name | Market cap | Study | Phase | Status | Interventions | Conditions | Enrollment | Start | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ONC | BeOne Medicines | $545.6B | A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell MalignanciesNCT05006716Phase 1: Number of Participants with Adverse Events (AEs) | Phase 1/2 | Recruiting | Drug: BGB-16673 | B-cell Malignancy, Marginal Zone Lymphoma, Follicular Lymphoma, Non-Hodgkin Lymphoma, Waldenström Macroglobulinemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, Diffuse Large B Cell Lymphoma | 645 | 2021-09-13 | Nov 2026 | ≤ 102 d | 2026-08-19 |
| ABBV | AbbVie | $457.5B | Study to Evaluate Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-291 Moves Through the Body in Adult Participants With Non-Hodgkin's LymphomaNCT06667687Percentage of Participants with Adverse Events (AE)s | Phase 1 | Active, not recruiting | Drug: ABBV-291 | Non-Hodgkin's Lymphoma | 21 | 2025-01-16 | Apr 2027 | ≤ 253 d | 2026-08-14 |
| AZN | AstraZeneca | — | Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHLNCT06526793Overall response rate (ORR) (central review) | Phase 2 | Recruiting | Drug: Surovatamig | B-cell Non-Hodgkin Lymphoma, Follicular Lymphoma (FL), Large B-Cell Lymphoma (LBCL) | 270 | 2024-11-27 | 2028-04-21 | in 610 d | 2026-08-13 |
| AZN | AstraZeneca | — | A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell MalignanciesNCT06564038Number of Participants with Adverse Events, Serious Adverse Events and Adverse Events of Special Interest | Phase 1/2 | Recruiting | Drug: Surovatamig, Prednisone (or equivalent), Rituximab, Cyclophosphamide, Vincristine, Doxorubicin, Acalabrutinib | Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma, Mantle-cell Lymphoma, Large B-cell Lymphoma, B-cell Non-Hodgkin Lymphoma | 408 | 2025-01-30 | 2029-06-11 | in 1,026 d | 2026-08-12 |
| LLY | Eli Lilly and Company | $1.15T | A Study of LY4584180 in Adult Participants With Previously Treated Blood CancersNCT07226843Number of Dose-Limiting Toxicities (DLTs) and DLT-Equivalent Toxicities | Phase 1 | Recruiting | Drug: LY4584180, Rituximab | Lymphoma, Non-Hodgkin's, Lymphoma, Diffuse Large B-Cell, Follicular Lymphoma | 460 | 2026-04-17 | Apr 2027 | ≤ 253 d | 2026-08-06 |
| NTRA | Natera, Inc. | $44.9B | Sample Collection for Ongoing Research and Product Evaluation Study - Non-Hodgkin Lymphoma (SCORE-NHL)NCT07750886observationalPrimary Outcome - Blood and Residual Tissue Specimen Collection from 160 Completed Participants for Blood-Based Cancer Monitoring and Detection and Cancer Assay Development. | — | Recruiting | — | Non-Hodgkin Lymphoma, T-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, High-Grade B-Cell Lymphoma, Primary Mediastinal B-Cell Lymphoma, Peripheral T-Cell Lymphoma, Transformed Follicular Lymphoma, Follicular Lymphoma Grade 3B, Follicular Lymphoma, Anaplastic Large Cell Lymphoma | 200 | 2026-07-27 | Apr 2032 | ≤ 2,080 d | 2026-08-06 |
| LYEL | Lyell Immunopharma, Inc. | $332M | A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell TherapyNCT07188558Event free survival | Phase 3 | Recruiting | Biological: rondecabtagene autoleucel, axicabtagene ciloleucel, lisocabtagene maraleucel | Large B-cell Lymphoma, Lymphoma, B-Cell, Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Non-Hodgkin Lymphoma Refractory/ Relapsed, Diffuse Large B Cell Lymphoma (DLBCL), Diffuse Large B Cell Lymphoma Refractory, Diffuse Large B Cell Lymphoma Relapsed | 400 | 2026-01-12 | Dec 2029 | ≤ 1,229 d | 2026-08-04 |
| REGN | Regeneron Pharmaceuticals | $76.1B | A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgkin Lymphoma Who Have Been Previously Treated With Other Cancer TherapiesNCT03888105Objective Response Rate (ORR), as assessed by independent central review | Phase 2 | Active, not recruiting | Drug: Odronextamab | B-cell Non-Hodgkin Lymphoma (B-NHL) | 515 | 2019-11-13 | 2026-06-17actual | — | 2026-07-31 |
| ADCT | ADC Therapeutics S.A. | $131M | A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)NCT04970901Number of Participants Who Experience a Dose-Limiting Toxicity (DLT) | Phase 1 | Active, not recruiting | Drug: Loncastuximab Tesirine, Polatuzumab Vedotin, Glofitamab, Mosunetuzumab, Obinutuzumab | B-Cell Non-Hodgkin Lymphoma, Relapsed B-Cell Non-Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma | 154 | 2022-06-17 | 2027-03-31 | in 223 d | 2026-07-17 |
| LLY | Eli Lilly and Company | $1.15T | Study of Oral LOXO-338 in Patients With Advanced Blood CancersNCT05024045Part 1 - To determine the maximum tolerated dose (MTD)/recommended phase 2 dose (RP2D) of oral LOXO-338 | Phase 1 | Completed | Drug: LOXO-338, Pirtobrutinib | Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-cell Marginal Zone, Lymphoma, Non-Hodgkin, Multiple Myeloma, B-cell Lymphoma, Waldenstrom Macroglobulinemia, Lymphoma, Mantle-Cell | 27 | 2021-09-30 | 2023-06-14actual | — | 2026-07-17 |
| ONC | BeOne Medicines | $545.6B | A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell MalignanciesNCT05828589Part 1: Number of participants with dose limiting toxicities (DLTs) | Phase 1 | Terminatedsponsor's stated reason: This decision is due to a company business decision with strategy change on the BGB-21447 development in B-cell malignancies and is not driven by safety concerns. | Drug: BGB-21447 | Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Relapsed Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia, Relapsed Follicular Lymphoma, Relapsed Marginal Zone Lymphoma, Relapse Diffuse Large B Cell Lymphoma, Relapsed Small Lymphocytic Lymphoma, Refractory Follicular Lymphoma, Refractory Marginal Zone Lymphoma, Refractory Small Lymphocytic Lymphoma, Richter Transformation, Refractory Diffuse Large B-cell Lymphoma, Transformed Non-Hodgkin Lymphoma | 51 | 2023-06-20 | 2026-06-08actual | — | 2026-07-14 |
| IBRX | ImmunityBio, Inc. | $8.2B | Study for Participants With Relapsed/Refractory Non-Hodgkin LymphomaNCT06334991Overall safety evaluation in combining CD19 t haNK as a single agent with rituximab | Phase 1 | Active, not recruiting | Biological: CD19 t-haNK | Non-Hodgkin Lymphoma Refractory/ Relapsed | 20 | 2024-08-23 | Oct 2027 | ≤ 437 d | 2026-07-10 |
| LLY | Eli Lilly and Company | $1.15T | A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )NCT07101328Phase 1 - Number of Participants with Dose Limiting Toxicities (DLT) of LY4152199 | Phase 1 | Recruiting | Drug: LY4152199 - IV | Lymphoma, Non-Hodgkin, B-cell Lymphoma, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular, Lymphoma, B-cell Marginal Zone, Waldenstrom Macroglobulinemia, Lymphoma, Mantle Cell | 215 | 2026-05-28 | Apr 2027 | ≤ 253 d | 2026-07-10 |
| 4568.T | Daiichi Sankyo | $31.7B | A First-in-Human Trial of DS3790a in Participants With Hematological MalignanciesNCT07220616Number of Participants Reporting Dose-limiting Toxicities, Treatment-emergent Adverse Events, Serious Adverse Events, Adverse Events of Special Interest, and Deaths in Participants With Hematological Malignancies | Phase 1/2 | Recruiting | Drug: DS3790a, Combination drug, Combination drug | Hematological Malignancies, B-cell Non-Hodgkin Lymphoma | 420 | 2026-01-16 | 2030-11-30 | in 1,563 d | 2026-07-09 |
| PFE | Seagen, a wholly owned subsidiary of Pfizer | $155.3B | A Safety Study of PF-08046045/SGN-35T in Adults With Advanced CancersNCT06120504Number of participants with adverse events (AEs) | Phase 1 | Terminatedsponsor's stated reason: Study terminated as part of strategic considerations | Drug: PF-08046045 | Lymphoma, T-Cell, Cutaneous, Hodgkin Disease, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Non-Hodgkin | 22 | 2024-02-29 | 2025-12-10actual | — | 2026-07-06 |
| AZN | AstraZeneca | — | A Phase I/II Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory B-cell Non-Hodgkin LymphomaNCT07123454Percentage of participants with dose-limiting toxicities (DLTs) | Phase 1/2 | Recruiting | Drug: AZD4512 | B-cell Non-Hodgkin Lymphoma | 91 | 2025-09-24 | 2028-03-01 | in 559 d | 2026-06-29 |
| BMY | Bristol-Myers Squibb | $134.9B | A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin LymphomaNCT05255601results2026-06-26Number of Participants With Dose-Limiting Toxicities (DLTs) - Part A | Phase 1/2 | Terminated | Drug: Relatlimab, Nivolumab | Lymphoma, Non-Hodgkin, Hodgkin Disease | 5 | 2022-09-13 | 2025-12-03actual | — | 2026-06-26 |
| AZN | AstraZeneca | — | AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.NCT06137144Incidence and severity of adverse events (AEs) and serious adverse events (SAEs) | Phase 1/2 | Recruiting | Drug: AZD3470, Pembrolizumab | Lymphoma, Non-Hodgkin Lymphoma, Hodgkin Lymphoma, Peripheral T-cell Lymphoma (PTCL), PTCL-NOS, ALCL, AITL | 161 | 2024-01-23 | 2029-05-03 | in 987 d | 2026-06-24 |
| AZN | AstraZeneca | — | A Study of AZD0486 in Subjects With B-Cell Non-Hodgkin LymphomaNCT04594642Incidence of subjects with Dose-limiting toxicities (DLT) | Phase 1 | Active, not recruiting | Drug: AZD0486 IV | B-cell Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Follicular Lymphoma | 226 | 2021-03-02 | 2028-06-19 | in 669 d | 2026-06-17 |
| LYEL | Lyell Immunopharma, Inc. | $332M | Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell LymphomaNCT05826535Phase 1: Evaluate the safety and tolerability of a single dose of ronde-cel administered as a single agent | Phase 1/2 | Recruiting | Drug: Rondecabtagene autoleucel (ronde-cel), Fludarabine, Cyclophosphamide | Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Large B-cell Lymphoma | 270 | 2023-05-09 | 2028-12-31 | in 864 d | 2026-05-28 |
| ABBV | AbbVie | $457.5B | An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical TrialNCT03844048Number of Participants With Adverse Events | Phase 3 | Active, not recruiting | Drug: Venetoclax | Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia, Multiple Myeloma, Non-Hodgkin's Lymphoma, Acute Lymphoblastic Leukemia, Cancer | 165 | 2019-09-06 | Aug 2027 | ≤ 376 d | 2026-05-13 |
| BMY | Bristol-Myers Squibb | $134.9B | A Rollover Study of CC-122NCT05688475Number of participants with serious adverse events (SAEs) for participants who received at least 1 dose of CC-122 | Phase 1 | Active, not recruiting | Drug: CC-122, Dexamethasone | Non-Hodgkin Lymphoma | 12 | 2023-04-11 | 2026-10-31 | in 72 d | 2026-05-11 |
| REGN | Regeneron Pharmaceuticals | $76.1B | A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin LymphomaNCT06230224Event-free survival (EFS) as assessed by independent central review (ICR) | Phase 3 | Active, not recruiting | Drug: Odronextamab, Ifosfamide, Carboplatin, Etoposide, Rituximab, Dexamethasone, Cisplatin, Cytarabine, Gemcitabine | B-Cell Non-Hodgkin Lymphoma (B-NHL) | 216 | 2024-02-15 | 2028-05-29 | in 648 d | 2026-05-11 |
| ABBV | AbbVie | $457.5B | Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 TabletsNCT05618028Number of Participants With Adverse Events (AE) | Phase 1 | Active, not recruiting | Drug: ABBV-525 | Diffuse Large B-Cell Lymphoma, Chronic Lymphocytic Leukemia, B Cell Malignancies, Non-Hodgkin's Lymphoma | 78 | 2023-04-04 | Jul 2029 | ≤ 1,076 d | 2026-05-04 |
| AAPG | Ascentage Pharma Group Inc. | — | A Study to Evaluate the Safety,PK and PD of APG-2575 in Patients With Hematologic MalignanciesNCT03913949Maximum Tolerated Dose (MTD) | Phase 1 | Active, not recruiting | Drug: APG-2575 | Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma | 74 | 2019-06-03 | 2024-10-20actual | — | 2026-05-01 |
| 4568.T | Daiichi Sankyo Co., Ltd. | $31.7B | DS-3201b in Participants With LymphomasNCT02732275Dose Escalation Period: Number of participants with dose-limiting toxicities (DLTs) | Phase 1 | Active, not recruiting | Drug: DS-3201b, DS-3201b | Lymphoma, Malignant, Non-hodgkin Lymphoma | 100 | 2016-03-31 | 2022-12-31actual | — | 2026-04-28 |
| NKTX | Nkarta, Inc. | $173M | NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell CancersNCT05020678Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] | Phase 1 | Active, not recruiting | Biological: NKX019 | Lymphoma, Non-Hodgkin, B-cell Acute Lymphoblastic Leukemia, Large B-cell Lymphoma, Mantle Cell Lymphoma, Indolent Lymphoma, Waldenstrom Macroglobulinemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Aggressive Lymphoma, Large-cell Lymphoma | 150 | 2021-08-20 | 2025-03-31actual | — | 2026-04-20 |
| LLY | Eli Lilly and Company | $1.15T | Long-Term Safety of Pirtobrutinib in Participants With Previously Treated Types of Blood CancersNCT07162181Percentage of Participants with Grade 3 or Higher Treatment-emergent Adverse Events | Phase 2 | Active, not recruiting | Drug: Pirtobrutinib | Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, B-cell Lymphoma | 13 | 2025-08-07 | May 2030 | ≤ 1,380 d | 2026-04-17 |
| IPH.PA | Innate Pharma | $170M | Phase1/2 Study of IPH6501 in Patients With Relapsed /Refractory B-Cell Non-Hodgkin LymphomaNCT06088654Safety and tolerability | Phase 1/2 | Terminatedsponsor's stated reason: Following Completion of dose escalation, the study has been discontinued as part of the Company's strategic priorization of its pipeline. | Drug: IPH6501 | Non Hodgkin Lymphoma | 23 | 2024-03-04 | 2026-02-06actual | — | 2026-04-14 |
| ACTU | Actuate Therapeutics Inc. | $25M | 9-ING-41 in Patients With Advanced CancersNCT03678883Parts 1/2: Number of participants with treatment-related adverse events as assessed by CTCAE v4.03 | Phase 2 | Active, not recruiting | Drug: 9-ING-41, Gemcitabine - 21 day cycle, Doxorubicin., Lomustine, Carboplatin., Nab paclitaxel., Paclitaxel., Gemcitabine - 28 day cycle, Irinotecan | Cancer, Pancreatic Cancer, Sarcoma, Renal Cancer, Refractory Cancer, Refractory Neoplasm, Refractory Non-Hodgkin Lymphoma, Pancreatic Adenocarcinoma, Resistant Cancer, Neoplasm Metastasis, Neoplasm of Bone, Neoplasm, Breast, Neoplasm of Lung, Neoplasms,Colorectal, Neoplasms Pancreatic, Malignant Glioma, Malignancies, Malignancies Multiple, Bone Metastases, Bone Neoplasm, Bone Cancer, Pancreas Cancer, Pancreatic Neoplasms, Breast Neoplasms, Acute T Cell Leukemia Lymphoma | 350 | 2019-01-04 | Jun 2026 | — | 2026-04-03 |
| ARTV | Artiva Biotherapeutics, Inc. | $571M | AB-101 as Monotherapy and With Immunotherapy in Patients With Relapsed/Refractory B-Cell Non-Hodgkin LymphomaNCT04673617Phase 1: Safety and tolerability of AB-101 as monotherapy, and in combination with rituximab (including the DLBCL specific cohort) and in combination with bendamustine and rituximab. | Phase 1/2 | Completed | Drug: AB-101, Rituximab, Interleukin-2, Cyclophosphamide, Fludarabine, Bendamustine | Non Hodgkin Lymphoma | 45 | 2021-03-29 | 2025-10-06actual | — | 2026-04-03 |
| CCCC | C4 Therapeutics, Inc. | $514M | Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple MyelomaNCT04756726Phase 1: Safety and tolerability of cemsidomide | Phase 1 | Active, not recruiting | Drug: cemsidomide, Dexamethasone Oral | Multiple Myeloma, Lymphoma, Non-Hodgkin's | 224 | 2021-04-27 | 2026-09-30 | in 41 d | 2026-03-25 |
| IBRX | ImmunityBio, Inc. | $8.2B | Study of CD19 t-haNK and NAI With Rituximab in Participants With Indolent Non-Hodgkin LymphomaNCT07477366ORR in accordance with Lymphoma Response to Immunomodulatory Therapy Criteria (LYRIC) | Phase 2 | Not yet recruiting | Biological: CD19 t-haNK- IV Administration · Drug: N-803, rituximab | Relapsed B-Cell Non-Hodgkin Lymphoma | 20 | Apr 2026 | Dec 2027 | ≤ 498 d | 2026-03-17 |
| CRBU | Caribou Biosciences, Inc. | $167M | Long-Term Follow-up StudyNCT05332054observationalIncidence of targeted NSAEs | — | Enrolling by invitation | Biological: Caribou-sponsored investigational therapy | Lymphoma, Non-Hodgkin, Relapsed Non-Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Lymphoma, B Cell Lymphoma, B-Cell Non-Hodgkin's Lymphoma, Hematologic Malignancy, Relapsed/Refractory Multiple Myeloma, Relapsed/Refractory Acute Myeloid Leukemia | 150 | 2022-03-16 | Dec 2041 | ≤ 5,612 d | 2026-03-12 |
| LLY | Eli Lilly and Company | $1.15T | A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) PirtobrutinibNCT06876649Percentage of Participants with a Grade ≥3 treatment-emergent AEs | Phase 4 | Recruiting | Drug: Pirtobrutinib | Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma | 787 | 2025-05-20 | May 2030 | ≤ 1,380 d | 2026-03-02 |
| LLY | Eli Lilly and Company | $1.15T | A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin LymphomaNCT06876662Percentage of Participants with a Grade ≥3 treatment-emergent adverse events (TEAEs) | Phase 4 | Recruiting | Drug: Pirtobrutinib | Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma | 279 | 2025-05-20 | May 2030 | ≤ 1,380 d | 2026-03-02 |
| HOWL | Werewolf Therapeutics, Inc. | $20M | A Phase 1b/2 Multisite Dose-finding and Expansion Study of WTX-330 in Adult Patients With Selected Advanced or Metastatic Solid Tumors or LymphomaNCT06939283Incidence of Dose Limiting Toxicities (DLTs) | Phase 1/2 | Active, not recruiting | Drug: WTX-330 | Advanced or Metastatic Solid Tumors, Non-Hodgkin Lymphoma | 100 | 2025-05-07 | Aug 2028 | ≤ 742 d | 2026-02-10 |
| LLY | Eli Lilly and Company | $1.15T | A Study of LOXO-305 in Chinese Participants With Blood Cancer (Including Lymphoma and Chronic Leukemia)NCT04849416results2024-07-16Primary Analysis Set (PAS): Overall Response Rate (ORR) Assessed by Independent Review Committee | Phase 2 | Completed | Drug: LOXO-305 | Leukemia, Lymphoid, Lymphoma, Non-Hodgkin, Lymphoma, Mantle-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone, Leukemia, Lymphocytic, Chronic, B-Cell | 87 | 2021-05-14 | 2023-04-10actual | — | 2026-02-06 |
| INCY | Incyte Corporation | $24.7B | A Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in Participants With Relapsed/Refractory Non Hodgkin Lymphoma (R/R NHL) or Chronic Lymphocytic Leukemia (CLL)NCT04809467results2026-01-29Number of Participants With Any Treatment-emergent Adverse Event (TEAE ) | Phase 1/2 | Terminatedsponsor's stated reason: A business decision was made to discontinue further enrollment. There were no safety concerns that contributed to this decision. | Drug: tafasitamab, parsaclisib | Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma | 54 | 2021-09-16 | 2024-10-22actual | — | 2026-02-04 |
| ABBV | AbbVie | $457.5B | Expanded Access to VenetoclaxNCT03123029expanded access | — | Available | Drug: Venetoclax | Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma, Acute Myeloid Leukemia (AML), Non-Hodgkin's Lymphoma, Acute Lymphoblastic Leukemia (ALL), Amyloidosis, Plasma Cell Leukemia | — | — | — | — | 2026-01-30 |
| BMY | Bristol-Myers Squibb | $134.9B | Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Second Primary MalignancyNCT06357754observationalParticipant in situ hybridization (ISH) or droplet-based digital Polymerase chain reaction (ddPCR) transgene testing results | — | Recruiting | Biological: Idecabtagene vicleucel, Lisocabtagene maraleucel | Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukaemia, Multiple Myeloma | 50 | 2023-10-06 | 2038-10-06 | in 4,430 d | 2026-01-22 |
| HOWL | Werewolf Therapeutics, Inc. | $20M | WTX-330 in Patients With Advanced or Metastatic Solid Tumors or Non-Hodgkin LymphomaNCT05678998results2026-01-06Incidence of Dose Limiting Toxicities (DLTs) | Phase 1 | Completed | Drug: WTX-330 | Advanced or Metastatic Solid Tumors, Non-Hodgkin Lymphoma | 25 | 2022-12-06 | 2024-12-23actual | — | 2026-01-06 |
| SNY | Sanofi | — | A Study to Evaluate the Safety and Activity of SAR448501/DR-0201 in Patients With Relapsed/ Refractory B-Cell Non-Hodgkin LymphomaNCT06392477Incidence of treatment-emergent adverse event (TEAE) | Phase 1 | Recruiting | Drug: SAR448501 | B-cell Non Hodgkin Lymphoma | 96 | 2024-07-08 | 2028-01-21 | in 519 d | 2025-12-23 |
| IPSC | Century Therapeutics, Inc. | $353M | A Study of CNTY-101 in Participants With CD19-Positive B-Cell MalignanciesNCT05336409Maximum Tolerated Dose (MTD) as Determined by the Percentage of Participants With Dose Limiting Toxicities (DLTs) and DLTs Based on Severity | Phase 1 | Terminatedsponsor's stated reason: Strategic decision | Biological: CNTY-101, IL-2 · Drug: Lymphodepleting Chemotherapy | R/R CD19-Positive B-Cell Malignancies, Indolent Non-Hodgkin Lymphoma, Aggressive Non-Hodgkin Lymphoma | 28 | 2023-01-24 | 2025-07-01actual | — | 2025-12-18 |
| SANA | Sana Biotechnology | $1.1B | Study Evaluating SC262 in Subjects With r/r Non-Hodgkin's Lymphoma (VIVID)NCT06285422Evaluate safety and tolerability of SC262 | Phase 1 | Active, not recruiting | Drug: SC262 | Non Hodgkin's Lymphoma, Large B-cell Lymphoma | 6 | 2024-04-18 | Dec 2025 | — | 2025-11-28 |
| CRSP | CRISPR Therapeutics AG | $5.1B | A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell MalignanciesNCT05643742Phase 1 (Dose Escalation): Incidence of adverse events, defined as dose-limiting toxicities | Phase 1/2 | Recruiting | Biological: CTX112 | B-cell Lymphoma, Non-Hodgkin Lymphoma, B-cell Malignancy, Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL), Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Large B-cell Lymphoma | 120 | 2023-03-10 | Jan 2030 | ≤ 1,260 d | 2025-11-14 |
| AAPG | Ascentage Pharma Group Inc. | — | A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NHLNCT04496349Maximum tolerated dose of APG-115 | Phase 2 | Recruiting | Drug: APG-115, APG-2575 | T-Prolymphocytic Leukemia, Non-Hodgkins Lymphoma | 78 | 2021-07-12 | 2026-05-31 | — | 2025-11-04 |
| CRSP | CRISPR Therapeutics AG | $5.1B | A Safety and Efficacy Study Evaluating CTX110 in Subjects With Relapsed or Refractory B-Cell Malignancies (CARBON)NCT04035434results2025-10-24Dose Escalation Phase 1: Number of Participants With Dose-limiting Toxicities (DLT) in NHL and B Cell ALL Population | Phase 1/2 | Terminatedsponsor's stated reason: Patients to be followed up in the CRSP-ONC-LTF study | Biological: CTX110 | B-cell Malignancy, Non-Hodgkin Lymphoma, B-cell Lymphoma, Adult B Cell ALL | 93 | 2019-07-22 | 2024-10-04actual | — | 2025-10-24 |
| BMY | Bristol-Myers Squibb | $134.9B | An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple MyelomaNCT01592370results2022-02-17Number of Participants That Experienced Drug Related Grade 3-4 AEs | Phase 1/2 | Completed | Biological: Nivolumab, Ipilimumab, Lirilumab, Daratumumab · Drug: Pomalidomide, Dexamethasone | Non-Hodgkin's Lymphoma, Hodgkin Lymphoma, Multiple Myeloma | 320 | 2012-08-02 | 2020-09-25actual | — | 2025-10-22 |
| REGN | Regeneron Pharmaceuticals | $76.1B | Study to Investigate the Safety and Tolerability of Odronextamab in Patients With CD20+ B-Cell MalignanciesNCT02290951Safety/overall frequency of adverse events (AEs) | Phase 1 | Completed | Drug: Odronextamab multiple dose levels, Odronextamab multiple dose levels | Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia | 200 | 2015-01-09 | 2025-08-21actual | — | 2025-10-10 |
| SANA | Sana Biotechnology | $1.1B | Study Evaluating SC291 in Subjects With r/r B-cell Malignancies (ARDENT)NCT05878184Evaluate safety and tolerability of SC291 | Phase 1 | Active, not recruiting | Drug: SC291 | Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia | 16 | 2023-05-02 | 2025-11-04 | — | 2025-10-02 |
| RCUS | Arcus Biosciences, Inc. | $3.8B | A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced MalignanciesNCT04772989Percentage of participants with Adverse Events | Phase 1 | Completed | Drug: AB308, Zimberelimab | Advanced Solid Tumor, Non Small Cell Lung Cancer (NSCLC), Melanoma, Cervical Cancer, Multiple Myeloma, Lymphoma, Non-Hodgkin, Diffuse Large B Cell Lymphoma (DLBCL), Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal Cancer | 94 | 2021-03-19 | 2025-08-25actual | — | 2025-08-28 |
| CLLS | Cellectis S.A. | — | Study Evaluating UCART20x22 in B-Cell Non-Hodgkin LymphomaNCT05607420Dose finding and expansion parts: Incidence of adverse events/serious adverse events/dose limiting toxicity [Safety and Tolerability] | Phase 1/2 | Recruiting | Biological: UCART20x22, CLLS52 | B-cell Non-Hodgkin Lymphoma (B-NHL) | 80 | 2022-11-01 | Aug 2027 | ≤ 376 d | 2025-08-24 |
| MRKR | Marker Therapeutics, Inc. | $19M | Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory LymphomaNCT05798897Dose Escalation | Phase 1 | Recruiting | Drug: MT-601 | Non-Hodgkin Lymphoma, Adult, Non-Hodgkin Lymphoma, Refractory, Non-Hodgkin Lymphoma, Relapsed, Non Hodgkin Lymphoma, Hodgkin Lymphoma, Hodgkin Lymphoma, Adult, Hodgkin's Lymphoma, Relapsed, Adult | 79 | 2023-01-02 | 2028-02-28 | in 557 d | 2025-08-20 |
| BMEA | Biomea Fusion Inc. | $98M | Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLLNCT05153330Determine Optimal Biologic Dose (OBD) and RP2D of BMF-219 monotherapy for (Cohorts 1, 2, 3 & 4) | Phase 1 | Terminatedsponsor's stated reason: Biomea Fusion, Inc., is no longer pursuing oncology indications for BMF-219. No safety concerns or efficacy observations led to this study closure. | Drug: BMF-219 | Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Acute Mixed-Phenotype Leukemia, Cancer, Refractory, Progression, Diffuse Large B Cell Lymphoma, Multiple Myeloma, Lymphoma, Lymphoma, Non-Hodgkin, Myeloma, Plasma-Cell, Myelomatosis, Plasma Cell Myeloma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 55 | 2022-01-24 | 2025-02-13actual | — | 2025-07-03 |
| GILD | Gilead Sciences | $177.9B | Trial of Magrolimab (Hu5F9-G4) in Combination With Rituximab or Rituximab + Chemotherapy in Participants With Relapsed/Refractory B-cell Non-Hodgkin's LymphomaNCT02953509results2025-05-29Phase 1b: Percentage of Participants Experiencing Dose-limiting Toxicities (DLTs) in Antibody Treatment Combination | Phase 1/2 | Terminatedsponsor's stated reason: Study terminated early due to the magrolimab program discontinuation. | Drug: Magrolimab, Rituximab, Gemcitabine, Oxaliplatin, Allopurinol | Non Hodgkin Lymphoma | 178 | 2016-11-21 | 2024-03-25actual | — | 2025-05-29 |
| CRBU | Caribou Biosciences, Inc. | $167M | CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)NCT04637763Primary outcome measures number of patients with dose-limiting toxicities (Part A). | Phase 1 | Unknown status | Genetic: CB-010 · Drug: Cyclophosphamide, Fludarabine | Lymphoma, Non-Hodgkin, Relapsed Non Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Non Hodgkin Lymphoma, Lymphoma, B Cell Lymphoma, B Cell Non-Hodgkin's Lymphoma | 72 | 2021-05-26 | Aug 2025 | — | 2025-03-24 |
| APRE | Aprea Therapeutics | $8M | APR-246 in Combination With Acalabrutinib or Venetoclax Based Therapy in Subjects With R/R Non Hodgkin Lymphomas (NHL)NCT04419389results2024-11-15To Determine the DLT of APR-246 in Combination With Acalabrutinib or in Combination With Venetoclax + Rituximab Therapy in Subjects With NHL, Including Subjects With R/R CLL, RT and R/R MCL. | Phase 1/2 | Terminatedsponsor's stated reason: Sponsor decision | Drug: APR-246 (eprenetapopt) + Acalabrutinib in CLL, APR-246 (eprenetapopt) 4.5 g/d + Venetoclax + Rituximab in CLL, APR-246 (eprenetapopt) 4.5 g/d + (Acalabrutinib, OR, (Venetoclax +Rituximab)), in CLL and/or MCL and/or RT, APR-246 (eprenetapopt) 4.5 g/d + Venetoclax + Rituximab in RT | Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma | 1 | 2021-03-02 | 2021-08-23actual | — | 2025-03-17 |
| APTOF | Aptose Biosciences Inc. | — | A Study of CG-806 in Patients With Relapsed or Refractory CLL/SLL or Non-Hodgkin's LymphomasNCT03893682Incidence of treatment-emergent adverse events of CG-806 | Phase 1 | Terminatedsponsor's stated reason: Change in corporate strategy | Drug: CG-806 | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Non-Hodgkin's Lymphoma | 36 | 2019-04-30 | 2024-05-17actual | — | 2025-03-07 |
| IBRX | ImmunityBio, Inc. | $8.2B | QUILT-3.052: NANT Non-Hodgkin Lymphoma (NHL) Vaccine: Combination Immunotherapy in Subjects With Relapsed CD20-positive NHLNCT03169790Incidence of treatment-emergent adverse events (AEs) and serious AEs (SAEs), graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03 | Phase 1/2 | Withdrawnsponsor's stated reason: Trial not initiated | Biological: avelumab, bevacizumab, ALT-803, ETBX-061, haNK · Drug: capecitabine, cyclophosphamide, 5-Fluorouracil (5-FU), leucovorin, nab-paclitaxel, Lovaza, Oxaliplatin, rituximab · Radiation: Stereotactic Body Radiation Therapy | Non Hodgkin Lymphoma | 0 | Dec 2017 | Jan 2019 | — | 2025-02-24 |
| ABBV | AbbVie | $457.5B | Safety Study of ABT-263 in Combination With Rituximab in Lymphoid CancersNCT00788684Extension Study: Continued assessment of the safety profile of ABT-263 when administered in combination with rituximab | Phase 1 | Completed | Drug: rituximab, ABT-263 | CD20-Positive Lymphoid Malignancies, Chronic Lymphoid Leukemia, Hematological Malignancies, Non-Hodgkin's Lymphoma | 29 | 2009-07-21 | 2025-02-07actual | — | 2025-02-20 |
| NKTR | Nektar Therapeutics | $2.5B | NKTR-255 vs Placebo Following CD19-directed CAR-T Therapy in Patients With Relapsed/Refractory Large B-cell LymphomaNCT05664217Complete response (CR) rate at month 6 | Phase 2/3 | Terminatedsponsor's stated reason: Sponsor decided to end the study | Drug: NKTR-255 at 1.5 µg/kg, NKTR-255 at 3.0 μg/kg, NKTR-255 at 3.0/6.0 μg/kg · Other: Placebo Comparator | Non-Hodgkin Lymphoma, Relapsed/Refractory Diffuse Large B-cell Lymphoma | 15 | 2022-12-23 | 2024-05-22actual | — | 2025-02-13 |
| AZN | AstraZeneca | — | A Phase I/II Study of AZD0466 as Monotherapy or in Combination With Anticancer Agents in Advanced Non-Hodgkin LymphomaNCT05205161results2025-01-07Number of Participants With Adverse Events (AE) | Phase 1 | Terminatedsponsor's stated reason: Due to safety reasons. | Drug: AZD0466 | Non-Hodgkin Lymphoma | 7 | 2022-07-05 | 2023-08-17actual | — | 2025-01-07 |
| KYMR | Kymera Therapeutics, Inc. | $10.1B | Safety, PK/PD, and Clinical Activity of KT-413 in Adult Patients with Relapsed or Refractory B-cell NHLNCT05233033To establish the Maximum Tolerated Dose (MTD) | Phase 1 | Completed | Drug: KT-413 | Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, DLBCL, MYD88 Gene Mutation | 7 | 2022-06-13 | 2023-07-28actual | — | 2024-12-10 |
| PFE | Pfizer | $155.3B | A Study to Learn About the Study Medicine (Maplirpacept) in People With Advanced Non-Hodgkin Lymphoma or Multiple Myeloma in ChinaNCT05896774Number of Participants With Dose-Limiting Toxicity (DLT) | Phase 1 | Completed | Drug: Maplirpacept | Non-Hodgkin Lymphoma, Multiple Myeloma | 10 | 2023-06-28 | 2024-11-06actual | — | 2024-11-20 |
| 4503.T | Astellas Pharma Inc | $26.0B | Cytomegalovirus (CMV) Vaccine in Donors and Recipients Undergoing Allogeneic Hematopoietic Cell Transplant (HCT)NCT00285259Safety of CMV immunotherapeutic vaccine in donors and recipients undergoing HCT | Phase 2 | Completed | Biological: VCL-CB01 · Other: Phosphate-buffered Saline (PBS) | Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Acute Myelogenous Leukemia, Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma, Myelodysplastic Syndrome | 112 | 2006-01-31 | 2009-11-30actual | — | 2024-10-21 |
| ZNTL | K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc. | $264M | Phase 1 First in Human Study of ZN-d5 as a Single AgentNCT04500587Observed Dose Limiting Toxicities | Phase 1 | Completed | Drug: ZN-d5 | Acute Myeloid Leukemia, Non Hodgkin Lymphoma | 39 | 2020-10-13 | 2023-12-12actual | — | 2024-09-19 |
| ADPT | Adaptive Biotechnologies | $3.9B | The clonoSEQ® Watch RegistryNCT04545333observationalDistribution of timepoints at which MRD is monitored using the clonoSEQ Assay in lymphoid malignancy patients in real world settings | — | Terminatedsponsor's stated reason: Sufficient data collected. | Diagnostic test: clonoSEQ Assay | Acute Lymphoblastic Leukemia, Adult B-Cell, Chronic Lymphocytic Leukemia, Multiple Myeloma, Non-hodgkin Lymphoma | 465 | 2020-10-13 | 2023-10-01actual | — | 2024-08-01 |
| MBIO | Mustang Bio | $14M | Study to Assess Safety, Tolerability and Efficacy of MB-106 in Patients With Relapsed or Refractory B-Cell NHL or CLLNCT05360238Phase 1: Primary objective | Phase 1/2 | Terminatedsponsor's stated reason: Business reasons | Biological: MB-106 | Follicular B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma Recurrent, Mantle Cell Lymphoma Refractory, Small Lymphocytic Lymphoma, Relapsed, Waldenstrom's Macroglobulinemia Recurrent, Waldenstrom's Macroglobulinemia Refractory, Chronic Lymphoid Leukemia in Relapse, B-cell Lymphoma Refractory | 20 | 2022-05-24 | 2024-04-12actual | — | 2024-07-22 |
| MBIO | Mustang Bio | $14M | Long-term Follow-up Study in Patients Previously Treated With a Mustang Bio CAR-T Cell Investigational Product.NCT05645744observationalAdverse events (AEs) | — | Terminatedsponsor's stated reason: Business Reasons | Biological: Prior MB-102 CAR-T cell investigational product., Prior MB-106 CAR-T cell investigational product. | Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), Chronic Lymphocytic Leukemia in Relapse, Small Lymphocytic Lymphoma, Relapsed, Waldenstrom's Macroglobulinemia Recurrent, Follicular B-cell Non-Hodgkin's Lymphoma, B-cell Lymphoma Refractory, Mantle Cell Lymphoma Recurrent, Hairy Cell Leukemia, Diffuse Large B Cell Lymphoma, Waldenstrom's Macroglobulinemia Refractory, Mantle Cell Lymphoma Refractory | 3 | 2021-09-29 | 2024-04-12actual | — | 2024-07-22 |
| TGTX | TG Therapeutics, Inc. | $7.7B | Study of TG-1701, an Irreversible Bruton's Tyrosine Kinase Inhibitor, in Patients With B-Cell MalignanciesNCT03671590Maximum Tolerated Dose acceptable for participants | Phase 1 | Terminatedsponsor's stated reason: Strategic/Business Decision | Drug: TG-1701, Umbralisib · Biological: Ublituximab | Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia | 172 | 2018-09-10 | 2024-05-21actual | — | 2024-07-19 |
| STRO | Sutro Biopharma, Inc. | $365M | Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell MalignanciesNCT03424603Part 1: Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability of STRO-001) | Phase 1 | Completed | Drug: STRO-001 | B-cell Lymphoma, Non Hodgkin Lymphoma, Multiple Myeloma, Follicular Lymphoma, Mantle Cell Lymphoma, Diffuse Large B Cell Lymphoma, Indolent Lymphoma, B Cells--Tumors | 70 | 2018-02-22 | 2024-02-15actual | — | 2024-06-11 |
| CLDX | Celldex Therapeutics | $3.3B | A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced MalignanciesNCT03329950Safety and Tolerability of CDX-1140 as assessed by CTCAE v5.0 | Phase 1 | Completed | Drug: CDX-1140, CDX-301, pembrolizumab, Chemotherapy | Melanoma, Non-small Cell Lung Cancer, Breast Cancer, Gastric Cancer, Renal Cell Carcinoma, Ovarian Cancer, Cholangiocarcinoma, Bladder Urothelial Carcinoma, Pancreatic Adenocarcinoma, Colorectal Cancer, Esophageal Cancer, Hepatic Cancer, Head and Neck Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer, Other Solid Tumors, Diffuse Large B-cell Lymphoma (DLBCL), Mantle Cell Lymphoma, Indolent B-cell Lymphomas, Non-Hodgkin Lymphoma, Follicular Lymphoma, Lymphoplasmacytic Lymphoma, Waldenstrom's Disease, Marginal Zone Lymphoma, Mucosa Associated Lymphoid Tissue, Small Lymphocytic Leukemia | 132 | 2017-12-01 | 2022-09-13actual | — | 2024-03-28 |
| AMGN | Amgen | $229.9B | A Phase 1b Open-Label Study Investigating the Safety and Pharmacokinetics of Administration of Subcutaneous Blinatumomab for the Treatment of Relapsed/Refractory Indolent Non-Hodgkin's LymphomaNCT02961881results2024-02-02Number of Participants With Dose Limiting-Toxicities (DLTs) After SC Administration | Phase 1 | Completed | Drug: blinatumomab | Non-Hodgkin's Lymphoma | 35 | 2017-09-18 | 2021-09-02actual | — | 2024-02-02 |
| PRLD | Prelude Therapeutics | $459M | PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell MalignanciesNCT05107856Dose limiting toxicities (DLT) of PRT1419 | Phase 1 | Terminatedsponsor's stated reason: Company Decision | Drug: PRT1419, Azacitidine, Venetoclax | Acute Myeloid Leukemia, B-cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelomonocytic Leukemia, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Myelodysplastic Syndromes, Myeloproliferative Neoplasm, Small Lymphocytic Lymphoma | 21 | 2022-03-22 | 2024-01-19actual | — | 2024-01-31 |
| CRVS | Corvus Pharmaceuticals, Inc. | $1.2B | CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced CancersNCT03454451Incidence of dose-limiting toxicities (DLTs) of CPI-006 as a single agent and in combination with ciforadenant and with pembrolizumab. | Phase 1 | Completed | Drug: CPI-006, CPI-006 + ciforadenant, CPI-006 + pembrolizumab, CPI-006, CPI-006 + ciforadenant, CPI-006 + pembrolizumab | Non-Small Cell Lung Cancer, Renal Cell Cancer, Colorectal Cancer, Triple Negative Breast Cancer, Cervical Cancer, Ovarian Cancer, Pancreatic Cancer, Endometrial Cancer, Sarcoma, Squamous Cell Carcinoma of the Head and Neck, Bladder Cancer, Metastatic Castration Resistant Prostate Cancer, Non-hodgkin Lymphoma | 117 | 2018-04-25 | 2022-12-28actual | — | 2023-12-21 |
| BIIB | Biogen | $31.4B | Zevalin® Followed by Rituxan® Maintenance in Previously Treated Low Grade Non-Hodgkin's LymphomaNCT00168727Determine overall response rate, event-free survival, time-to-progression, time-to-next-therapy, and freedom-from-relapse in pts with low-grade lymphoma in first or second relapse treated with Zevalin® followed by 2 yrs of Rituxan maintenance therapy | Phase 4 | Completed | Drug: ibritumomab tiuxetan (Zevalin®) | Lymphoma, Non-Hodgkin, Lymphoma, Low-Grade | 12 | 2003-06-01 | — | — | 2023-08-23 |
| EXEL | Exelixis | $13.2B | Study of XL114 in Subjects With Non-Hodgkin's LymphomaNCT05144347Dose-Escalation Stage: Recommended Dose (RD) and/or Maximum Tolerated Dose (MTD) for XL114 | Phase 1 | Terminatedsponsor's stated reason: Due to Sponsor reasons. | Drug: XL114 | Non-Hodgkin's Lymphoma (NHL), Activated B-Cell Type Diffuse Large B-Cell Lymphoma (ABC-DLBCL), Mantle Cell Lymphoma (MCL), Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) | 2 | 2022-04-12 | 2022-11-01actual | — | 2023-07-11 |
| NKTR | Nektar Therapeutics | $2.5B | NKTR-255 in Relapsed/Refractory Multiple Myeloma & Non-Hodgkin LymphomaNCT04136756Incidence of Treatment-Emergent Adverse Events and Serious Adverse Events of NKTR-255 as a single agent | Phase 1 | Completed | Drug: NKTR-255, NKTR-255 Q21, Rituximab, Daratumumab | Multiple Myeloma, Non-Hodgkin Lymphoma, Indolent Non-Hodgkin Lymphoma | 30 | 2019-10-07 | 2023-04-24actual | — | 2023-06-15 |
| GILD | Gilead Sciences | $177.9B | Study of GS-0189 (Formerly FSI-189) as Monotherapy and in Combination With Rituximab in Participants With Relapsed/Refractory Non-Hodgkin LymphomaNCT04502706Percentage of Participants Experiencing Treatment-Emergent Adverse Events | Phase 1 | Terminatedsponsor's stated reason: Sponsor's decision to discontinue development of this molecule | Drug: GS-0189, Rituximab | Non-hodgkin Lymphoma | 9 | 2020-11-17 | 2022-03-31actual | — | 2023-06-05 |
| ABBV | AbbVie | $457.5B | A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory MalignanciesNCT03236857Number of Participants Experiencing Adverse Events | Phase 1 | Completed | Drug: chemotherapy, venetoclax | Malignancies, Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Non-Hodgkin's Lymphoma, Neuroblastoma | 143 | 2017-11-08 | 2023-04-19actual | — | 2023-05-22 |
| AMGN | Amgen | $229.9B | Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological MalignanciesNCT03465540results2023-04-12Number of Participants Who Experienced a Dose-limiting Toxicity (DLT) | Phase 1 | Terminatedsponsor's stated reason: Strategic decisions | Drug: AMG 397, Dexamethasone, Azacitidine | Multiple Myeloma, Acute Myeloid Leukemia, Non-Hodgkins Lymphoma, Myelodysplastic Syndrome, AML, MDS, NHL | 24 | 2018-08-17 | 2019-07-25actual | — | 2023-04-12 |
| DTIL | Precision BioSciences, Inc. | $227M | Dose-escalation Study of Safety of PBCAR20A in Subjects With r/r NHL or r/r CLL/SLLNCT04030195results2023-01-31Maximum Tolerated Dose (MTD) | Phase 1/2 | Completed | Genetic: PBCAR20A · Drug: Fludarabine, Cyclophosphamide | Non-Hodgkin's Lymphoma, Relapsed, Chronic Lymphoid Leukemia in Relapse, Non-Hodgkin's Lymphoma Refractory, Chronic Lymphocytic Leukemia, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-cell Chronic Lymphocytic Leukemia, B-cell Non Hodgkin Lymphoma, Small Lymphocytic Lymphoma | 18 | 2020-03-24 | 2021-06-24actual | — | 2023-01-31 |
| 4523.T | Eisai Co., Ltd. | $8.7B | Study of Tazemetostat in Participants With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma With EZH2 Gene MutationNCT03456726results2022-12-16Objective Response Rate (ORR) Based on Independent Reviewer Assessment | Phase 2 | Completed | Drug: Tazemetostat | Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma | 20 | 2018-04-09 | 2021-12-17actual | — | 2022-12-16 |
| TGTX | TG Therapeutics, Inc. | $7.7B | Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin LymphomaNCT01647971Number of Participants with Adverse Events as a Measure of Safety and Tolerability | Phase 1/2 | Completed | Drug: Ublituximab | Non-Hodgkins Lymphoma, B-cell Lymphoma, Waldenstrom's Macroglobulinemia, Marginal Zone Lymphoma, Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Primary Central Nervous System Lymphoma | 39 | 2012-07-19 | May 2015actual | — | 2022-11-21 |
| AAPG | Ascentage Pharma Group Inc. | — | Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or LymphomasNCT05415098Dose-limiting Toxicity (DLT) | Phase 1 | Unknown status | Drug: APG-5918 | Nasopharyngeal Carcinoma, Castrate Resistant Prostate Cancer, Gastric Cancer, Ovarian Clear Cell Carcinoma, Mesothelioma, Sarcoma, Non Hodgkin Lymphoma, B Cell Lymphoma, Epithelioid Sarcoma | 90 | 2022-09-30 | 2024-09-30 | — | 2022-11-16 |
| PRLD | Prelude Therapeutics | $459M | A Study of PRT1419 in Patients With Relapsed/Refractory Hematologic MalignanciesNCT04543305To describe dose limiting toxicities (DLT) of PRT1419 | Phase 1 | Completed | Drug: PRT1419 | Multiple Myeloma, Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Myelodysplastic Syndromes | 16 | 2020-09-28 | 2022-03-21actual | — | 2022-11-15 |
| 4523.T | Eisai Co., Ltd. | $8.7B | A Study of Tazemetostat in Participants With Relapsed or Refractory B-cell Non-Hodgkin's LymphomaNCT03009344results2022-11-10Number of Participants With Dose-limiting Toxicities (DLTs) | Phase 1 | Completed | Drug: Tazemetostat | Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma | 7 | 2017-01-10 | 2017-07-12actual | — | 2022-11-10 |
| AMGN | Amgen | $229.9B | Study to Assess if ABP798 is Safe & Effective in Treating Non Hodgkin Lymphoma Compared to RituximabNCT02747043results2020-08-18Percentage of Participants Who Responded (Overall Response Rate - ORR) by Week 28 Based on Independent Central Assessment of Disease | Phase 3 | Completed | Biological: ABP 798, Rituximab | Lymphoma, Non-Hodgkin | 256 | 2016-05-25 | 2019-06-28actual | — | 2022-09-10 |
| TGTX | TG Therapeutics, Inc. | $7.7B | Phase I/II Study of Venetoclax or Lenalidomide in Combination With Ublituximab and Umbralisib in Subjects With Relapsed or Refractory CLL/SLL and NHLNCT03379051Determine Acceptable Adverse Events That Are Related to Treatment | Phase 1/2 | Terminatedsponsor's stated reason: Strategic/Business Decision | Drug: Venetoclax, Umbralisib, Lenalidomide · Biological: Ublituximab | Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma | 78 | 2018-03-27 | 2022-05-26actual | — | 2022-08-22 |
| TGTX | TG Therapeutics, Inc. | $7.7B | Study of Cosibelimab in Subjects With Relapsed or Refractory LymphomaNCT03778073Adverse Events That Are Related to Treatment | Phase 1 | Terminatedsponsor's stated reason: Strategic/Business Decision | Drug: Cosibelimab, Cosibelimab + Ublituximab + Bendamustine combination, Cosibelimab + Ublituximab + Bendamustine combination | B-cell Non Hodgkin Lymphoma, Richter's Transformation | 18 | 2019-04-17 | 2022-05-03actual | — | 2022-08-22 |
| TGTX | TG Therapeutics, Inc. | $7.7B | Extension Trial of Ublituximab and TGR-1202 in Combination or as Single Agents in Subjects Currently Receiving Treatment on Ublituximab and/or TGR-1202 TrialsNCT03207256Adverse Events of TGR-1202 and/or TGR-1202 + ublituximab treatment, including delayed toxicities | Phase 2 | Terminatedsponsor's stated reason: Strategic/Business Decision | Drug: TGR-1202, TGR-1202 + Ublituximab | Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma | 51 | 2017-08-09 | 2022-05-25actual | — | 2022-07-21 |
| TGTX | TG Therapeutics, Inc. | $7.7B | Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid MalignanciesNCT01744912Maximum Tolerated Dose acceptable for participants | Phase 1 | Terminatedsponsor's stated reason: Sponsor's decision | Drug: Ublituximab, Lenalidomide | Non-Hodgkins Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, B-cell Lymphomas, Marginal Zone Lymphoma, Mantle Cell Lymphoma, Waldenstrom's Macroglobulinemia | 10 | 2012-11-21 | 2014-02-07actual | — | 2022-05-11 |
| LLY | Eli Lilly and Company | $1.15T | A Study of LY3023414 in Participants With Advanced CancerNCT01655225Recommended Phase 2 dose | Phase 1 | Completed | Drug: LY3023414, Midazolam, Fulvestrant, Pemetrexed, Cisplatin, Abemaciclib, Letrozole | Advanced Cancer, Metastatic Cancer, Non-Hodgkin's Lymphoma, Metastatic Breast Cancer, Malignant Mesothelioma, Non-small Cell Lung Cancer | 156 | 2012-07-31 | 2019-04-04actual | — | 2022-04-08 |
| ABBV | AbbVie | $457.5B | A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia and Non-Hodgkin LymphomaNCT01328626Determination of dose limiting toxicity (DLT), maximum tolerated dose (MTD), recommended phase two dose (RPTD), and lead-in period regimen | Phase 1 | Completed | Drug: ABT-199 | Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma | 222 | 2011-05-23 | 2020-05-08actual | — | 2022-02-23 |
| ABBV | AbbVie | $457.5B | A Study of Venetoclax and AMG 176 in Patients With Relapsed/Refractory Hematologic MalignanciesNCT03797261Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RPTD) for Venetoclax + AMG 176 | Phase 1 | Terminatedsponsor's stated reason: Safety | Drug: Venetoclax, AMG 176 | Acute Myeloid Leukemia, Non-Hodgkin's Lymphoma, Diffuse Large B-cell Lymphoma | 9 | 2019-03-18 | 2019-12-30actual | — | 2021-12-07 |
| AZN | AstraZeneca | — | Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological MalignanciesNCT03263637Incidence of adverse events | Phase 1 | Completed | Drug: AZD4573 | Relapsed or Refractory Haematological Malignancies Including, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia, High Risk Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, Richter's Syndrome, B-cell Non-Hodgkin Lymphoma, T-cell Non-Hodgkin Lymphoma, Small Lymphocytic Lymphoma, Multiple Myeloma | 44 | 2017-10-24 | 2021-09-30actual | — | 2021-10-22 |
| GILD | Gilead Sciences | $177.9B | Phase I/II Study of hLL1-DOX in Relapsed NHL and CLLNCT01585688Evaluate the safety and tolerability of hLL1-DOX | Phase 1/2 | Terminatedsponsor's stated reason: Study was terminated due to lack of efficacy, as a result, the stability program for the drug product was discontinued | Drug: hLL1-DOX (IMMU-115) | Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia | 13 | Aug 2012 | Nov 2016actual | — | 2021-10-08 |
| TGTX | TG Therapeutics, Inc. | $7.7B | Evaluate the Safety and Efficacy of TGR 1202 in Patients With Relapsed or Refractory Hematologic MalignanciesNCT01767766Maximum Tolerated Dose acceptable for participants | Phase 1 | Completed | Drug: TGR-1202 | Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, Peripheral T-Cell Lymphoma, Hodgkin's Lymphoma | 90 | 2013-01-07 | Feb 2018actual | — | 2021-08-23 |
| GILD | Gilead Sciences | $177.9B | Treatment of Non-Hodgkin's Lymphoma With 90Y-hLL2 IgGNCT00061425 | Phase 1/2 | Completed | Drug: radiolabeled epratuzumab | Non-Hodgkin's Lymphoma, Lymphoma, B-Cell | — | Aug 2000 | Nov 2007actual | — | 2021-08-19 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
How Non-Hodgkin Lymphoma is matched — 22 exact registry spellings
A study is on this page when its ClinicalTrials.gov record names one of these conditions exactly (letter case aside). Nothing is matched by substring or stem, so a longer condition that merely contains one of these words is a different page. The list was curated by hand and last measured 2026-08-19; a spelling filed by only one study was not curated, so the counts here are a floor rather than the registry's own total for the disease.
- Non-Hodgkin's Lymphoma
- Non-Hodgkin Lymphoma
- Lymphoma, Non-Hodgkin
- Non Hodgkin Lymphoma
- Non-Hodgkins Lymphoma
- B-cell Non-Hodgkin Lymphoma
- Lymphoma, Non-Hodgkin's
- B-cell Non Hodgkin Lymphoma
- Indolent Non-Hodgkin Lymphoma
- Refractory Non-Hodgkin Lymphoma
- Relapsed Non-Hodgkin Lymphoma
- Indolent Non-Hodgkin's Lymphoma
- Non-Hodgkin's Lymphoma (NHL)
- Refractory B-Cell Non-Hodgkin Lymphoma
- B-cell Non-Hodgkin Lymphoma (B-NHL)
- Follicular B-cell Non-Hodgkin's Lymphoma
- Indolent Non-Hodgkin's Lymphomas
- Non Hodgkin's Lymphoma
- Non-Hodgkin
- Non-Hodgkin Lymphoma Refractory/ Relapsed
- Relapsed B-Cell Non-Hodgkin Lymphoma
- Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
Permalink · All conditions · Catalyst calendar · Every registered study · Search the whole pipeline for “Non-Hodgkin Lymphoma” (a text search, wider than this page)